Platinum-Resistant Malignant Female Reproductive System Neoplasm

Platinum-Resistant Malignant Female Reproductive System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

112 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 58
Recruiting: 30
Ph III recruiting: 3
Growth YoY: —
Industry share: 47%
Top sponsor: National Cancer Institute (NCI)
Termination share: 53.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (25)

clinicaltrialsPublishedShowing 51–56 of 56 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02889900	Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer(CONCERTO)	completed	Phase 2	62	AstraZenecaINDUSTRY	1	Mar 8, 2022	clinicaltrials
NCT04068974	Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer	unknown	Phase 2	28	Peking Union Medical College HospitalOTHER	1	Mar 16, 2021	clinicaltrials